Tampa General Hospital Achieves Prestigious FACT Accreditation
FACT Accreditation represents a gold seal of quality and safety in the world of stem cell transplant and cellular therapy.
As they continue to provide leading-edge cancer care, Tampa General Hospital (TGH) and the TGH Cancer Institute have been awarded accreditation by the Foundation for the Accreditation of Cellular Therapy (FACT). This prestigious recognition highlights the academic health system's dedication to clinical excellence, innovation, and patient safety in stem cell transplant and cellular therapy.
The Importance of FACT Accreditation
FACT is a nonprofit organization that sets forth standards for high-quality medical and laboratory practices in cellular therapies. Receiving FACT accreditation assures that a program meets recognized international standards and utilizes best practices in patient care, cell collection, processing, and administration. The accreditation is acknowledged by the U.S. Food and Drug Administration and The Joint Commission, among others.
Sword of Excellence in Cancer Care
"Tampa General is honored to be recognized by FACT," stated Dr. Eduardo Sotomayor, vice president and executive director of the TGH Cancer Institute. "We strive to provide innovative treatments to our patients. This accreditation signifies our continual efforts to develop the Cancer Institute into a world-class, research-driven resource for cancer patients."
Innovative Treatments Offered
The TGH Cancer Institute's cellular therapy program encompasses immune effector cell therapy, including Chimeric Antigen Receptor (CAR) T-cell therapy, and stem cell transplant suitable for patients with aggressive blood cancers such as lymphomas and leukemias. These advanced treatments exemplify the innovative approach TGH employs to care for its patients.
Leading the charge in these advancements is Dr. Ivan Borrello, a hematologist oncologist and medical director of the Myeloma, Bone Marrow Transplant (BMT) and Cell Therapies program. Since joining Tampa General in 2022 from Johns Hopkins, he has been pivotal in enhancing BMT and CAR T therapies.
"As we work to develop options for patients with complex cancers, we focus on offering novel immune-based therapies to elevate our Bone Marrow Transplant and Cell Therapies Unit into a nationally recognized program," Dr. Borrello remarked. "Being acknowledged by FACT for our commitment to excellence in health care is a significant honor."
Focus on Patient Care
A dedicated team of cell therapy nurses, practitioners, and social workers ensures patients receive comprehensive care within a specialized inpatient BMT unit and the outpatient Cellular-Immunotherapy Transplant Unit. This model of care supports a holistic approach to treatment, emphasizing both clinical excellence and compassionate support.
Leadership in Oncology
This accreditation is a milestone affirming TGH's leadership in cellular therapy and serves as a guarantee for patients that their treatment is administered with outstanding skill and empathy. Dr. Abraham Schwarzberg, executive vice president and chief of Oncology, expressed pride in this achievement. He stated, "This milestone not only affirms TGH's leadership in cellular therapy but offers patients the reassurance of expert care delivered with precision and compassion."
Tampa General Hospital stands as Florida's sole hospital backed by academic medicine, partnering with the USF Health Morsani College of Medicine. The TGH Cancer Institute is recognized among the top 10% of hospitals nationally by U.S. News & World Report. It provides groundbreaking treatments, advanced diagnostic imaging, and a well-coordinated approach to deliver world-class patient care.
Comprehensive Cancer Care and Future Developments
As a prominent center for sensible care, TGH offers a spectrum of services often rivaled by larger institutions. The Cancer Institute has received extensive accolades, including certifications by the American College of Surgeons and the American Society of Clinical Oncology for meeting stringent standards required in the field.
With its ongoing commitment to healthcare excellence, Tampa General Hospital not only addresses immediate cancer treatment needs but enhances innovative practices that predictively shape patient care landscapes in the future. The facility's expansive outreach includes several hospitals and outpatient services that reflect its dedication to community wellness and comprehensive health management.
A Lasting Impact
As Tampa General continues to evolve in response to patient needs and healthcare advancements, it proudly defines itself through robust, research-driven initiatives. With a confident step towards the future, this institution shows no signs of slowing, remaining dedicated to providing outstanding care and groundbreaking treatments that uplift its community and serve as a beacon of hope in oncology.
Frequently Asked Questions
What is FACT accreditation?
FACT accreditation signifies that an institution meets high standards for safety and quality in areas like stem cell transplants and cellular therapies.
Why is Tampa General Hospital notable?
Tampa General is recognized for its exceptional cancer care, advanced treatments, and comprehensive health services in Florida.
What treatments are offered at the TGH Cancer Institute?
The TGH Cancer Institute provides innovative therapies such as CAR T-cell therapy and stem cell transplants for aggressive blood cancers.
Who leads the cancer therapies at TGH?
Dr. Ivan Borrello, a hematologist oncologist, is at the forefront of leading BMT and CAR T-cell therapies at TGH.
What is the significance of being recognized by FACT?
Being recognized by FACT highlights an institution's commitment to excellence in cancer care and reassures patients about the quality of their treatment.
